Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition-Reference-Cited by-同舟云学术

Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition

Published:2017-07-29 Issue:4 Volume:80 Page:861-867
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Srinivasan Gayathri,Sidhu Gurjit Singh,Williamson Elizabeth A.,Jaiswal Aruna S.,Najmunnisa Nasreen,Wilcoxen Keith,Jones Dennie,George Thomas J.,Hromas Robert^ORCID

Funder

National Institutes of Health

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/article/10.1007/s00280-017-3401-y/fulltext.html

Reference20 articles.

1. Kondola S, Manners D, Nowak AK (2016) Malignant pleural mesothelioma: an update on diagnosis and treatment options. Ther Adv Respir Dis 10:275–288. doi: 10.1177/1753465816628800

2. Gomez D, Tsao AS (2014) Local and systemic therapies for malignant pleural mesothelioma. Curr Treat Options Oncol 15:683–699. doi: 10.1007/s11864-014-0314-4

3. Taioli E, Wolf AS, Camacho-Rivera M et al (2015) Determinants of survival in malignant pleural mesothelioma: a surveillance, epidemiology, and end results (SEER) Study of 14,228 Patients. PLoS One. doi: 10.1371/journal.pone.0145039

4. Bueno R, Stawiski EW, Goldstein LD et al (2016) Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet 48:407–416. doi: 10.1038/ng.3520

5. Nasu M, Emi M, Pastorino S et al (2015) High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol 10:565–576. doi: 10.1097/JTO.0000000000000471

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genomic characterization and detection of potential therapeutic targets for peritoneal mesothelioma in current practice;Clinical and Experimental Medicine;2024-04-20

2. The genetic susceptibility in the development of malignant pleural mesothelioma: somatic and germline variants, clinicopathological features and implication in practical medical/surgical care: a narrative review;Journal of Thoracic Disease;2024-01

3. Clinical Next Generation Sequencing Application in Mesothelioma: Finding a Golden Needle in the Haystack;Cancers;2023-12-06

4. Pleural Mesothelioma: Treatable Traits of a Heterogeneous Disease;Cancers;2023-12-06

5. Complete clinical remission of malignant peritoneal mesothelioma with systemic pemetrexed and bevacizumab in a patient with a BAP1 mutation;BMJ Case Reports;2023-12